These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
110 related articles for article (PubMed ID: 22267869)
41. An Immunohistochemical Investigation of Renal Phospholipidosis and Toxicity in Rats. Ma JY; Snook S; Garrovillo S; Johnson C; La D Int J Toxicol; 2017; 36(5):386-394. PubMed ID: 28820006 [TBL] [Abstract][Full Text] [Related]
42. Effect of selective LRRK2 kinase inhibition on nonhuman primate lung. Fuji RN; Flagella M; Baca M; Baptista MA; Brodbeck J; Chan BK; Fiske BK; Honigberg L; Jubb AM; Katavolos P; Lee DW; Lewin-Koh SC; Lin T; Liu X; Liu S; Lyssikatos JP; O'Mahony J; Reichelt M; Roose-Girma M; Sheng Z; Sherer T; Smith A; Solon M; Sweeney ZK; Tarrant J; Urkowitz A; Warming S; Yaylaoglu M; Zhang S; Zhu H; Estrada AA; Watts RJ Sci Transl Med; 2015 Feb; 7(273):273ra15. PubMed ID: 25653221 [TBL] [Abstract][Full Text] [Related]
43. Assessment of the morphology and significance of the lymph nodal and hepatic lesions produced in rats by the feeding of certain mineral oils and waxes. Proceedings of a pathology workshop held at the Fraunhofer Institute of Toxicology and Aerosol Research Hannover, Germany, May 7-9, 2001. Carlton WW; Boitnott JK; Dungworth DL; Ernst H; Hayashi Y; Mohr U; Parodi AL; Pattengale PK; Rittinghausen S; Ward JM Exp Toxicol Pathol; 2001 Sep; 53(4):247-55. PubMed ID: 11665848 [TBL] [Abstract][Full Text] [Related]
44. Epididymal and systemic phospholipidosis in rats and dogs treated with the dopamine D3 selective antagonist PNU-177864. Rudmann DG; McNerney ME; VanderEide SL; Schemmer JK; Eversole RR; Vonderfecht SL Toxicol Pathol; 2004; 32(3):326-32. PubMed ID: 15204974 [TBL] [Abstract][Full Text] [Related]
45. Amphiphilic cationic drugs and phospholipids influence the activities of beta-galactosidase and beta-glucosidase from liver lysosomal fraction of untreated rats. Harder A; Dodt G; Debuch H Biol Chem Hoppe Seyler; 1985 Feb; 366(2):189-93. PubMed ID: 2985099 [TBL] [Abstract][Full Text] [Related]
46. Ultrastructural, physico-chemical and conformational study of the interactions of gentamicin and bis(beta-diethylaminoethylether) hexestrol with negatively-charged phospholipid layers. Mingeot-Leclercq MP; Schanck A; Ronveaux-Dupal MF; Deleers M; Brasseur R; Ruysschaert JM; Laurent G; Tulkens PM Biochem Pharmacol; 1989 Mar; 38(5):729-41. PubMed ID: 2539158 [TBL] [Abstract][Full Text] [Related]
47. Kidney injury biomarkers in hypertensive, diabetic, and nephropathy rat models treated with contrast media. Rouse RL; Stewart SR; Thompson KL; Zhang J Toxicol Pathol; 2013; 41(4):662-80. PubMed ID: 23085980 [TBL] [Abstract][Full Text] [Related]
48. Biomarkers of drug-induced skeletal muscle injury in the rat: troponin I and myoglobin. Vassallo JD; Janovitz EB; Wescott DM; Chadwick C; Lowe-Krentz LJ; Lehman-McKeeman LD Toxicol Sci; 2009 Oct; 111(2):402-12. PubMed ID: 19628585 [TBL] [Abstract][Full Text] [Related]
49. Liposome electrokinetic chromatography based in vitro model for early screening of the drug-induced phospholipidosis risk. Wang T; Feng Y; Jin X; Fan X; Crommen J; Jiang Z J Pharm Biomed Anal; 2014 Aug; 96():263-71. PubMed ID: 24814828 [TBL] [Abstract][Full Text] [Related]
50. Urinary biomarkers in hydronephrosis. Madsen MG Dan Med J; 2013 Feb; 60(2):B4582. PubMed ID: 23461995 [TBL] [Abstract][Full Text] [Related]
51. In vitro detection of drug-induced phospholipidosis using gene expression and fluorescent phospholipid based methodologies. Nioi P; Perry BK; Wang EJ; Gu YZ; Snyder RD Toxicol Sci; 2007 Sep; 99(1):162-73. PubMed ID: 17567588 [TBL] [Abstract][Full Text] [Related]
52. Predicting cisplatin-induced acute kidney injury by urinary neutrophil gelatinase-associated lipocalin excretion: a pilot prospective case-control study. Gaspari F; Cravedi P; MandalĂ M; Perico N; de Leon FR; Stucchi N; Ferrari S; Labianca R; Remuzzi G; Ruggenenti P Nephron Clin Pract; 2010; 115(2):c154-60. PubMed ID: 20407275 [TBL] [Abstract][Full Text] [Related]
53. In vitro validation of drug-induced phospholipidosis. Park S; Choi YJ; Lee BH J Toxicol Sci; 2012; 37(2):261-7. PubMed ID: 22467016 [TBL] [Abstract][Full Text] [Related]
54. Quantitative Assessment of Drug Delivery to Tissues and Association with Phospholipidosis: A Case Study with Two Structurally Related Diamines in Development. Loryan I; Hoppe E; Hansen K; Held F; Kless A; Linz K; Marossek V; Nolte B; Ratcliffe P; Saunders D; Terlinden R; Wegert A; Welbers A; Will O; Hammarlund-Udenaes M Mol Pharm; 2017 Dec; 14(12):4362-4373. PubMed ID: 29099189 [TBL] [Abstract][Full Text] [Related]
55. Gentamicin or chlorphentermine induction of phospholipidosis in the developing organism: role of tissue and species in manifestation of toxicity. Kacew S J Pharmacol Exp Ther; 1985 Jan; 232(1):239-43. PubMed ID: 3965695 [TBL] [Abstract][Full Text] [Related]
56. Impact of Pathologists and Evaluation Methods on Performance Assessment of the Kidney Injury Biomarker, Kim-1. Rouse R; Min M; Francke S; Mog S; Zhang J; Shea K; Stewart S; Colatsky T Toxicol Pathol; 2015 Jul; 43(5):662-74. PubMed ID: 25520306 [TBL] [Abstract][Full Text] [Related]
57. Identification of urinary miRNA biomarkers for detecting cisplatin-induced proximal tubular injury in rats. Kanki M; Moriguchi A; Sasaki D; Mitori H; Yamada A; Unami A; Miyamae Y Toxicology; 2014 Oct; 324():158-68. PubMed ID: 24863737 [TBL] [Abstract][Full Text] [Related]
58. Evaluation of putative biomarkers of nephrotoxicity after exposure to ochratoxin a in vivo and in vitro. Rached E; Hoffmann D; Blumbach K; Weber K; Dekant W; Mally A Toxicol Sci; 2008 Jun; 103(2):371-81. PubMed ID: 18308701 [TBL] [Abstract][Full Text] [Related]